Context Therapeutics Inc. (CNTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Context Therapeutics Inc. (CNTX) trades at $0.64 with AI Score 40/100 (Grade C). Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for women's cancers. Market cap: $58.58M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CNTX: CNTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNTX: 1/1 perspectives are bearish.
How is this calculated? →Context Therapeutics Inc. (CNTX) Healthcare & Pipeline Overview
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in treatments for women's cancers. Their lead candidate, ONA-XR, addresses progesterone receptor-linked resistance, a key obstacle in hormone-dependent cancers. The company also develops novel bispecific antibodies, positioning them in the innovative oncology therapeutics market.
What Is the Investment Thesis for CNTX?
Context Therapeutics Inc. presents a notable research candidate within the women's cancer therapeutics market. The company's lead product candidate, ONA-XR, targets a critical resistance mechanism in hormone-dependent cancers, potentially unlocking significant value. Positive clinical trial data for ONA-XR could drive substantial stock appreciation. The development of CLDN6xCD3 bsAb, a novel bispecific antibody, adds another layer of potential upside. A successful partnership or acquisition could also provide significant returns. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established pharmaceutical companies. With a market cap of $58.58M and a beta of 1.83, Context Therapeutics offers high-risk, high-reward potential for investors seeking exposure to innovative cancer therapies.
Based on FMP financials and quantitative analysis
CNTX Key Highlights
- Market capitalization of $58.58M reflects the company's current valuation in the biotechnology sector.
- Beta of 1.83 indicates higher volatility compared to the overall market, typical for clinical-stage biopharmaceutical companies.
- Lead product candidate, ONA-XR, targets a significant unmet need in hormone-dependent cancers.
- Development of CLDN6xCD3 bsAb represents a novel approach to cancer immunotherapy.
- Collaboration with Integral Molecular, Inc. strengthens the company's research and development capabilities.
Who Are CNTX's Competitors?
CNTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| PFE Pfizer Inc. | $23.72 | -2.47% | 136B | 64 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNTX's Key Strengths?
- Innovative drug candidates targeting unmet needs in women's cancers.
- Proprietary technology and intellectual property.
- Experienced management team with expertise in drug development.
- Strategic collaborations with other companies and research institutions.
What Are CNTX's Weaknesses?
- Clinical-stage company with no currently approved products.
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures and regulatory setbacks.
- Small number of employees.
What Could Drive CNTX Stock Higher?
- Data readout from ongoing clinical trials of ONA-XR in hormone-dependent cancers.
- IND filing for CLDN6xCD3 bsAb.
- Enrollment of patients in clinical trials of ONA-XR.
- Progress in strategic collaborations with other companies and research institutions.
What Are the Key Risks for CNTX?
- Financial-distress signal — its Altman Z-Score of 0.90 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-60.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected adverse events.
- Regulatory delays or rejection of drug candidates.
- Competition from other companies developing similar therapies.
- Dependence on external funding to support research and development activities.
What Are the Growth Opportunities for CNTX?
- Advancement of ONA-XR through clinical trials: The successful completion of ongoing and planned clinical trials for ONA-XR in various hormone-dependent cancers represents a significant growth opportunity. Positive data could lead to regulatory approvals and commercialization, potentially generating substantial revenue. The market for therapies addressing resistance to anti-hormonal treatments in breast and gynecological cancers is estimated to be worth billions of dollars annually. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
- Development and commercialization of CLDN6xCD3 bsAb: The development of CLDN6xCD3 bsAb, a bispecific antibody targeting Claudin 6, offers another avenue for growth. Claudin 6 is overexpressed in various cancers, making it an attractive target for immunotherapy. Successful development and commercialization of this therapy could expand Context Therapeutics' product portfolio and address a broader range of cancers. Market size for bispecific antibodies in oncology is rapidly growing, with projections reaching several billion dollars in the next few years. Timeline: Preclinical and early clinical development with potential for IND filing in the next 18-24 months.
- Expansion of the pipeline through strategic collaborations: Context Therapeutics can expand its pipeline by entering into strategic collaborations with other biotechnology companies or research institutions. This could provide access to new technologies, targets, and drug candidates, accelerating the company's growth. The market for licensing and collaboration agreements in the biotechnology industry is highly active, with numerous opportunities for companies to partner and share resources. Timeline: Ongoing efforts to identify and secure strategic collaborations.
- Out-licensing or partnering of ONA-XR for specific indications: Context Therapeutics could out-license or partner ONA-XR for specific indications or geographic regions. This would allow the company to leverage the resources and expertise of larger pharmaceutical companies to accelerate the development and commercialization of ONA-XR. The market for out-licensing and partnering agreements in the pharmaceutical industry is robust, with numerous deals being announced each year. Timeline: Potential for out-licensing or partnering agreements in the next 12-24 months.
- Acquisition by a larger pharmaceutical company: Context Therapeutics could be acquired by a larger pharmaceutical company seeking to expand its oncology pipeline. The company's innovative technologies and promising drug candidates could make it an attractive acquisition target. The market for mergers and acquisitions in the pharmaceutical industry is highly active, with numerous deals being announced each year. Timeline: Potential for acquisition in the next 2-3 years, depending on clinical trial progress and market conditions.
What Opportunities Does CNTX Have?
- Successful completion of clinical trials and regulatory approvals for ONA-XR and CLDN6xCD3 bsAb.
- Expansion of the pipeline through strategic collaborations and acquisitions.
- Out-licensing or partnering of drug candidates for specific indications or geographic regions.
- Acquisition by a larger pharmaceutical company.
What Threats Does CNTX Face?
- Competition from established pharmaceutical companies with greater resources.
- Changes in regulatory requirements and healthcare policies.
- Economic downturns and market volatility.
- Unexpected adverse events in clinical trials.
What Are CNTX's Competitive Advantages?
- Proprietary drug candidates: Context Therapeutics owns the rights to its innovative drug candidates, such as ONA-XR and CLDN6xCD3 bsAb, providing a competitive advantage.
- Targeting resistance mechanisms: The company's focus on addressing resistance to existing cancer therapies creates a unique value proposition.
- Strategic collaborations: Partnerships with companies like Integral Molecular, Inc. enhance the company's research and development capabilities.
- Experienced management team: The company's management team has extensive experience in drug development and commercialization.
What Does CNTX Do?
Context Therapeutics Inc., founded in 2015 and headquartered in Philadelphia, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for women's cancers. The company's primary focus is on addressing unmet needs in hormone-driven cancers, where resistance to existing therapies poses a significant challenge. Their lead product candidate, onapristone extended release (ONA-XR), is a potent and selective antagonist of the progesterone receptor (PR). The progesterone receptor is implicated in resistance to various cancer therapeutics, including anti-estrogen therapies, across a range of female hormone-dependent cancers. ONA-XR is designed to overcome this resistance, potentially improving outcomes for patients. In addition to ONA-XR, Context Therapeutics is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody. This innovative therapy aims to redirect T-cell-mediated lysis toward malignant cells that express Claudin 6 (CLDN6), a protein often overexpressed in various cancers. The company has a collaboration and licensing agreement with Integral Molecular, Inc. to further the development of this anti-claudin 6 bispecific monoclonal antibody for gynecologic cancer therapy. Context Therapeutics is committed to advancing its pipeline through clinical development, with the goal of providing new and effective treatment options for women battling cancer.
What Products and Services Does CNTX Offer?
- Develops onapristone extended release (ONA-XR), a progesterone receptor antagonist for hormone-dependent cancers.
- Focuses on treating cancers affecting women, such as breast and gynecological cancers.
- Creates bispecific antibodies like CLDN6xCD3 bsAb to target malignant cells.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with other companies, such as Integral Molecular, Inc., to advance its research and development efforts.
- Aims to overcome resistance to existing cancer therapies through novel mechanisms of action.
- Seeks regulatory approvals for its drug candidates from agencies like the FDA.
How Does CNTX Make Money?
- Develops and patents novel therapeutic drug candidates for women's cancers.
- Conducts preclinical and clinical research to validate the safety and efficacy of its drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization of approved drugs.
- Generates revenue through licensing fees, milestone payments, and royalties on sales of partnered drugs.
What Industry Does CNTX Operate In?
Context Therapeutics operates within the biotechnology industry, specifically targeting the women's cancer therapeutics market. This market is characterized by significant unmet needs and growing demand for innovative treatments. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing therapies for similar indications. The overall oncology market is projected to reach hundreds of billions of dollars in the coming years, driven by an aging population and increasing cancer incidence. Context Therapeutics aims to capture a share of this market by addressing resistance mechanisms and developing novel immunotherapies.
Who Are CNTX's Key Customers?
- Patients with hormone-dependent cancers, such as breast and gynecological cancers.
- Oncologists and other healthcare professionals who treat these patients.
- Pharmaceutical companies that may license or partner with Context Therapeutics to commercialize its drugs.
- Hospitals and cancer centers that may use Context Therapeutics' drugs to treat patients.
FY2026 estForward Outlook
Wall Street analysts project Context Therapeutics Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-0.39. The estimate reflects 8 contributing analysts.
ROE -60%Key Financial Metrics
Return on equity for Context Therapeutics Inc. stands at -60.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -68.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -64.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -76.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Context Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.90 places it in the distress zone, a signal of elevated financial risk.
CNTX Valuation & Market Position
With a $58.58M market cap, Context Therapeutics Inc. sits in the micro-cap segment of the market. Relative to its peer group, CNTX's quantitative score of 40/100 is below the peer average of 73/100.
CNTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, a positive signal.
- The community's bullish sentiment is building, indicating growing confidence in the company's direction.
- Market perception seems to be shifting positively, with more mentions of potential catalysts.
- Despite broader market uncertainty, CNTX is holding its ground, hinting at underlying strength.
Bear Case
- Insider activity, while showing buys, also reveals sales, creating mixed signals for investors.
- Bearish community voices highlight concerns about trial timelines and potential delays.
- Market perception also reflects worries about competition in the oncology space.
- Recent market developments indicate increased risk aversion, which could disproportionately affect smaller biotech firms like CNTX.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
CNTX Latest News
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Jun 15, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 9, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jun 5, 2026
CNTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNTX.
Price Targets
Wall Street price target analysis for CNTX.
CNTX MoonshotScore
What does this score mean?
The MoonshotScore rates CNTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Martin A. Lehr
CEO
Martin A. Lehr is the Chief Executive Officer of Context Therapeutics Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology drug development and commercialization. He has held leadership positions at various biotechnology companies, where he was responsible for overseeing clinical trials, regulatory submissions, and business development activities. Lehr's expertise spans a range of therapeutic areas, including women's health and cancer. He is known for his strategic vision and ability to build and lead high-performing teams.
Track Record: Under Martin Lehr's leadership, Context Therapeutics has advanced its lead product candidate, ONA-XR, through clinical development. He has also overseen the expansion of the company's pipeline through the development of CLDN6xCD3 bsAb and strategic collaborations. Lehr has successfully raised capital to fund the company's research and development activities and has built a strong team of scientists and business professionals. He manages a team of 12 employees.
Context Therapeutics Inc. Healthcare Stock: Key Questions Answered
What does Context Therapeutics Inc. do?
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for women's cancers. Their lead product candidate, onapristone extended release (ONA-XR), is a potent and selective antagonist of the progesterone receptor, which is linked to resistance for various classes of cancer therapeutics. They are also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody, designed to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company collaborates with Integral Molecular, Inc. for further development of this antibody for gynecologic cancer therapy.
What do analysts say about CNTX stock?
As a clinical-stage biopharmaceutical company, analyst coverage on Context Therapeutics Inc. (CNTX) is likely focused on the potential of its drug pipeline, particularly ONA-XR and CLDN6xCD3 bsAb. Valuation metrics would heavily rely on projected future revenues based on successful clinical trial outcomes and regulatory approvals. Growth considerations center around the company's ability to advance its drug candidates through clinical development and secure partnerships or out-licensing agreements. Analyst opinions are subject to change based on new data and market conditions.
What are the main risks for CNTX?
Context Therapeutics Inc. faces typical risks associated with clinical-stage biopharmaceutical companies. These include the potential for clinical trial failures, regulatory delays or rejections, and competition from other companies developing similar therapies. The company is also dependent on external funding to support its research and development activities, which could be affected by market conditions and investor sentiment. Additionally, unexpected adverse events in clinical trials could negatively impact the company's prospects.
What is Context Therapeutics Inc.'s drug pipeline status?
Context Therapeutics Inc.'s pipeline is centered around ONA-XR, currently in clinical trials for hormone-dependent cancers, and CLDN6xCD3 bsAb, in preclinical and early clinical development. The company is focused on advancing these candidates through the clinical development process, with key therapeutic areas including breast and gynecological cancers. Upcoming catalysts include data readouts from ongoing clinical trials of ONA-XR and the potential for an IND filing for CLDN6xCD3 bsAb. The pipeline reflects a strategic focus on addressing unmet needs in women's cancer treatment.
What revenue streams does Context Therapeutics Inc. have in healthcare?
As a clinical-stage biopharmaceutical company, Context Therapeutics Inc. currently does not have revenue from marketed products. Potential future revenue streams are contingent upon the successful development, regulatory approval, and commercialization of its drug candidates. These revenue streams could include product sales, licensing fees, milestone payments, and royalties on sales of partnered drugs. The company's revenue model is dependent on the success of its pipeline and strategic partnerships.
What are the key factors to evaluate for CNTX?
Context Therapeutics Inc. (CNTX) holds an AI score of 40/100 (low). Not financial advice.
How frequently does CNTX data refresh on this page?
CNTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNTX's recent stock price performance?
Context Therapeutics Inc. (CNTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug candidates targeting unmet needs in women's cancers. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes and regulatory approvals are uncertain and could impact the company's prospects.